Veracyte, Inc. (VCYT)

Market Cap	2.69B
Revenue (ttm)	399.58M
Net Income (ttm)	-54.04M
Shares Out	76.81M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	44.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	686,552
Open	34.22
Previous Close	34.31
Day's Range	33.56 - 35.02
52-Week Range	18.61 - 35.51
Beta	1.67
Analysts	Strong Buy
Price Target	35.67 (+1.97%)
Earnings Date	Nov 6, 2024

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis sy...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 815
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Financial Performance

In 2023, Veracyte's revenue was $361.05 million, an increase of 21.76% compared to the previous year's $296.54 million. Losses were -$74.40 million, 103.5% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for VCYT stock is "Strong Buy." The 12-month stock price forecast is $35.67, which is an increase of 1.97% from the latest price.

Price Target

$35.67

(1.97% upside)

Analyst Consensus: Strong Buy